CalciMedica, Inc. (CALC) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 La Jolla, CA, 미국. 현재 CEO는 A. Rachel Leheny.
CALC 을(를) 보유 IPO 날짜 2023-06-14, 14 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $10M.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
